References
- Meropol NJ, Schulman KA. Cost of cancer care: issues and implications. J Clin Oncol 2007;25:180–186.
- Reeder CE, Gordon D. Managing oncology costs. Am J Manag Care 2006;12(Suppl. 1):S3–S16; quiz S17–S19.
- Nava-Ocampo AA, Alarcón-Almanza JM, Moyao-García D, et al. Undocumented drug utilization and drug waste increase costs of pediatric anesthesia care. Fundam Clin Pharmacol 2004;18:107–112.
- Gillerman RG, Browning RA. Drug use inefficiency: a hidden source of wasted health care dollars. Anesth Analg 2000;91:921–924.
- Fasola G, Aita M, Marini L, et al. Drug waste minimisation and cost-containment in Medical Oncology: two-year results of a feasibility study. BMC Health Serv Res 2008;8:70.
- Clark L, Castro AP, Fortes AF, et al. Ideal vial size for bortezomib: real-world data on waste and cost reduction in treatment of multiple myeloma in Brazil. Value Health 2011;14(Suppl.):S82–S84.
- Cancer Care Ontario. Drug Formulary. 1 October 2013. Available from: www.cancercare.on.ca/toolbox/drugformulary/
- VIDAZA (azacitidine for injection) [product monograph]. Revised 2012. Mississauga, ON: Celgene Inc.
- Walker SE, Iazzetta J, De Angelis C, et al. Chemotherapy waste reduction through shelf-life extension. Can J Hosp Pharm 1994;47: 15–23.
- Duriez A, Vigneron JH, Zenier HA, et al. Stability of azacitidine suspensions. Ann Pharmacother 2011;45:546.
- Walker SE, Charbonneau LF, Law S, et al. Stability of azacitidine in sterile water for injection. Can J Hosp Pharm 2012;65:352–359.
- Prica A, Tseng E, Wells R, et al. Predictors of azacitidine response: a prospective longitudinal assessment. Leuk Res 2013;47(Suppl. 1):S80–S81.
- Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419–425.
- Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndromes: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006;24:3895–3903.